Dimerix Limited announced the appointment of Dr. Ash Soman, MD, as Chief Medical Officer and a member of the company's executive management team. Dr. Soman will lead the Company's multiple global clinical development programs and medical affairs at a pivotal time in Dimerix evolution. Dr. Soman, a highly experienced clinician, has over 30 years' experience spanning hospital clinical practice, clinical study design, medical affairs, compliance, patient safety and corporate strategy, having worked in big pharma, small biotech and clinical research organisations.

Dr. Soman has prior clinical training in general and respiratory medicine, working with patients suffering from both chronic kidney and respiratory diseases, and has assisted drug launches for the SGLT2 inhibitor dapagliflozin (indicated in diabetes and kidney disease) and coronary artery disease. Most recently, Dr. Soman was the Medical Director for the global CRO, IQVIA, where he managed strategy, early phase clinical trial design, development and oversight for emerging biotech companies in multiple therapy areas, including COVID-19. Dr. Soman will transition to full time following completion of his notice requirements from his prior role - expected to be no later than 25th April 2022.